Difference between revisions of "Talquetamab (Talvey)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/talquetamab NCI Drug Dictionary]: A bispecific humanized monoclonal antibody...") |
Warner-admin (talk | contribs) m (Text replacement - "/CD3 bispecific" to "-CD3 bispecific") |
||
(13 intermediate revisions by 2 users not shown) | |||
Line 2: | Line 2: | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/talquetamab NCI Drug Dictionary]: A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/talquetamab NCI Drug Dictionary]: A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. | ||
− | == | + | ==Toxicity management== |
− | + | *[https://www.tec-talrems.com/ Link to REMS program] | |
− | |||
+ | ==Diseases for which it is established== | ||
+ | *[[Multiple myeloma]] | ||
+ | |||
+ | ==History of changes in FDA indication== | ||
+ | *'''2023-08-09:''' Granted accelerated approval for adults with relapsed or refractory [[multiple myeloma]] who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. ''(Based on MonumenTAL-1)'' | ||
==Also known as== | ==Also known as== | ||
− | *'''Code | + | *'''Code name:''' JNJ-64407564 |
+ | *'''Generic name:''' talquetamab-tgvs | ||
+ | *'''Brand name:''' Talvey | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
− | + | [[Category:Anti-GPRC5D-CD3 bispecific antibodies]] | |
− | [[Category:Anti-GPRC5D | ||
− | |||
− | [[Category:Multiple myeloma medications | + | [[Category:Multiple myeloma medications]] |
− | [[Category: | + | [[Category:FDA approved in 2023]] |
+ | [[Category:REMS program]] |
Latest revision as of 00:13, 18 October 2023
Mechanism of action
From the NCI Drug Dictionary: A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells.
Toxicity management
Diseases for which it is established
History of changes in FDA indication
- 2023-08-09: Granted accelerated approval for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (Based on MonumenTAL-1)
Also known as
- Code name: JNJ-64407564
- Generic name: talquetamab-tgvs
- Brand name: Talvey